| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kalvista Pharmaceuticals, Inc. (KALV) has 12 insiders with recent SEC Form 4 filings, including 8 buys and 7 sells. KALV is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 462.6K | $12.49M | - | |
| Other | 223.5K | $6.03M | - | |
| Other | 142.5K | $3.85M | - | |
| Other | 100.0K | $2.70M | - | |
| Other | 51.4K | $1.39M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2025 | Yea Christopher53 | Chief Development Officer | Sale+OE | 2,601 | $9.82 | $25,552.74 | -2.7% | +23.4% | +58.0% | |
| Feb 18, 2025 | Audhya Paul K. | Chief Medical Officer | Sale+OE | 3,125 | $9.82 | $30,700.62 | -3.0% | +23.4% | +58.0% | |
| Feb 18, 2025 | Palleiko Benjamin L46 | Chief Executive Officer | Sale+OE | 5,104 | $9.82 | $50,142.72 | -1.8% | +23.4% | +58.0% | |
| Feb 13, 2025 | Venrock Healthcare Capital Partners Iii, L.P.54 | 10% Owner | Buy | 161,700 | $9.27 | $1,498,661.00 | +1.6% | +19.0% | +56.5% | |
| Feb 11, 2025 | Venrock Healthcare Capital Partners Iii, L.P.54 | 10% Owner | Buy | 104,489 | $9.26 | $967,144.93 | +0.7% | +31.4% | +67.3% | |
| Feb 3, 2025 | Venrock Healthcare Capital Partners Iii, L.P.54 | 10% Owner | Buy | 70,023 | $8.88 | $621,628.02 | +0.5% | +42.1% | +74.9% | |
| Dec 9, 2024 | Palleiko Benjamin L46 | Chief Executive Officer | Sale+OE | 7,627 | $9.75 | $74,363.25 | -2.7% | +28.4% | +73.0% | |
| Nov 26, 2024 | Audhya Paul K. | Chief Medical Officer | Sale+OE | 2,187 | $9.87 | $21,586.13 | -2.2% | +3.8% | +41.3% | |
| Nov 26, 2024 | Yea Christopher53 | Chief Development Officer | Sale+OE | 1,963 | $9.87 | $19,378.34 | -2.1% | +3.8% | +41.3% | |
| Nov 18, 2024 | Palleiko Benjamin L46 | Chief Executive Officer | Sale+OE | 14,400 | $9.26 | $133,293.60 | -5.1% | +5.2% | +53.4% |